- cafead   Apr 03, 2019 at 12:42: PM
via Mylan famously classified EpiPen as a generic on Medicaid when it should have been in the innovative drug class—a move that cut Mylan's rebate tally by hundreds of millions of dollars. Now, lawmakers have passed a bill cracking down on those misclassifications.
article source
article source